POSB133 Translating Findings from Affirm-AHF: Events Avoided and Cost Savings Associated with the Use of Ferric Carboxymaltose for the Treatment of Iron Deficiency in Patients with Acute Heart Failure with Reduced Ejection Fraction in Italy

Heart failure with reduced ejection fraction (HFrEF) imposes a significant burden on patients and healthcare systems. Iron deficiency (ID) is common this patient population and places additional burden as ID in patients with HFrEF is associated with poor quality of life and increased risk of hospitalisation and mortality. The objective of this analysis was to estimate the cost consequence of introducing FCM for the treatment of ID in patients with HFrEF from the perspective of healthcare payers in Italy.